Int J Enteric Pathog. 2013;1(1): e9344. doi: 10.17795/ijep9344

Research Article

Antibiotic Susceptibility of Helicobacter pylori Clinical Isolates in Hamadan, West of Iran

Cited by CrossRef: 6

1- Talebi Bezmin Abadi A. Helicobacter pylori treatment: New perspectives using current experience. Journal of Global Antimicrobial Resistance. 2017;8:123 [Crossref]
2- Manzouri L, Zarei F, Niazi N, Sedaghattalab M. Comparison of the Success Rate of Quadruple and Triple Antibiotic Therapy in Eradicating Helicobacter pylori Infection in Southwest of Iran: A Randomized Clinical Trial. Int J Infect. 2017;4(3) [Crossref]
3- Fakheri H, Saberi Firoozi M, Bari Z. Eradication of Helicobacter Pylori in Iran: A Review. Middle East J Dig Dis. 2017;10(1):5 [Crossref]
4- Khademi F, Sahebkar A, Vaez H, Arzanlou M, Peeridogaheh H. Characterization of clarithromycin-resistant Helicobacter pylori strains in Iran: A systematic review and meta-analysis. Journal of Global Antimicrobial Resistance. 2017;10:171 [Crossref]
5- Tarhini M, Fayyad-Kazan M, Fayyad-Kazan H, Mokbel M, Nasreddine M, Badran B, Kchour G. First-line treatment of Helicobacter pylori in Lebanon: Comparison of bismuth-containing quadruple therapy versus 14-days sequential therapy. Microbial Pathogenesis. 2018;117:23 [Crossref]
6- Feizabadi M. International Journal of Enteric Pathogens: A Highly Demanded Journal by Different Specialties. Int J Enteric Pathog. 2013;1(2):34 [Crossref]